Whole Body MRI in Oncology
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above.
• Participant is willing and able to give informed consent for participation in the study.
• Male or Female, aged ≥ 18 years.
• Life expectancy greater than 3 months.
Locations
Other Locations
Italy
IRCCS - Azienda Ospedaliero-Universitaria di Bologna - Policlinico di S. Orsola
RECRUITING
Bologna
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
RECRUITING
Meldola
IRCCS Istituto Europeo di Oncologia S.r.l.
NOT_YET_RECRUITING
Milan
Contact Information
Primary
Oriana Nanni
cc.ubsc@irst.emr.it
+390543739266
Backup
Bernadette Vertogen
cc.ubsc@irst.emr.it
+390544286058
Time Frame
Start Date: 2023-10-26
Estimated Completion Date: 2031-10
Participants
Target number of participants: 1000
Treatments
Patients affected by Monoclonal plasma cell disorders
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Multiple Myeloma (MM).
Patients affected by advanced prostate cancer (APC) or advanced breast cancer (ABC)
Patients affected by advanced prostate (APC) or breast cancer (ABC) with high suspicious of metastasis particularly in case of diagnostic doubt in other imaging methods (Computed tomography (CT), Positron Emission Computed Tomography (PET/CT), Bone Scintigraphy (BS)).
Patients affected by Lymphomas.
Patients affected by Lymphomas.
Related Therapeutic Areas
Sponsors
Leads: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS